MTOR and renal cell carcinoma: Likewise NETs share signaling pathways with renal cell carcinoma (RCC) and interestingly in RCC statins are known to inhibit the phosphorylation of AKT, mammalian target of rapamycin (mTOR), and ERK reducing cells motility [39].